Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
| Revenue (TTM) | $29.74B |
| Gross Profit (TTM) | $23.60B |
| EBITDA | $14.74B |
| Operating Margin | 39.30% |
| Return on Equity | 43.40% |
| Return on Assets | 13.30% |
| Revenue/Share (TTM) | $23.92 |
| Book Value | $18.93 |
| Price-to-Book | 6.93 |
| Price-to-Sales (TTM) | 5.67 |
| EV/Revenue | 5.97 |
| EV/EBITDA | 12.26 |
| Quarterly Earnings Growth (YoY) | 54.80% |
| Quarterly Revenue Growth (YoY) | 4.40% |
| Shares Outstanding | $1.24B |
| Float | $1.24B |
| % Insiders | 0.12% |
| % Institutions | 92.12% |
Volatility is currently expanding
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding trading day.
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Trodelvy is now approved in first-line mTNBC either as a single agent for patients who are not candidates f.
Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.
Gilead Sciences offers a compelling long-term value opportunity after a significant pullback, with a "Buy" rating reaffirmed. GILD's core HIV franchise drives 72% of sales, with robust growth from Biktarvy and rapid adoption of Yeztugo, now expected to reach $1 billion in annual sales. Management raised 2026 revenue growth guidance to 5.5% at midpoint, citing strong HIV performance and momentum in oncology with Trodelvy.
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
